An Open-label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Jan 2014
Price : $35 *
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen
- 27 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Nov 2013 New trial record
- 01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.